David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

neoadjuvant chemotherapy alone WILMINGTON, Del., March 31, 2025--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...

Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.50%, which has investors questioning if this is right time to buy.

2 Cheng Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313-1327. 3 National Cancer Institute. NCI dictionary - small cell lung ...

The 24-month metastasis-free survival rate was 75.1% in the durvalumab arm and 65.1% in the control arm. Perioperative durvalumab improves upon neoadjuvant chemotherapy in patients with cisplatin ...